| Developmental pharmacokinetics in pediatric populations H Lu, S Rosenbaum The Journal of Pediatric Pharmacology and Therapeutics 19 (4), 262-276, 2014 | 374 | 2014 |
| Basic pharmacokinetics and pharmacodynamics: An integrated textbook and computer simulations SE Rosenbaum John Wiley & Sons, 2016 | 217 | 2016 |
| Physician reporting of adverse drug reactions: results of the Rhode Island adverse drug reaction reporting project HD Scott, A Thacher-Renshaw, SE Rosenbaum, WJ Waters, M Green, ... Jama 263 (13), 1785-1788, 1990 | 179 | 1990 |
| Rhode Island physicians' recognition and reporting of adverse drug reactions HD Scott, SE Rosenbaum, WJ Waters, AM Colt, LG Andrews, JP Juergens, ... Rhode Island Medical Journal 70 (7), 311-316, 1987 | 125 | 1987 |
| Knowledge of and attitudes about adverse drug reaction reporting among Rhode Island pharmacists JA Generali, MA Danish, SE Rosenbaum Annals of Pharmacotherapy 29 (4), 365-369, 1995 | 75 | 1995 |
| A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase III clinical trial KA Jackson, SE Rosenbaum, BM Kerr, YK Pithavala, G Yuen, MN Dudley Antimicrobial agents and chemotherapy 44 (7), 1832-1837, 2000 | 44 | 2000 |
| Population pharmacokinetics of mycophenolic acid and its 2 glucuronidated metabolites in kidney transplant recipients WJ Sam, F Akhlaghi, SE Rosenbaum The Journal of Clinical Pharmacology 49 (2), 185-195, 2009 | 40 | 2009 |
| Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients SE Rosenbaum, G Baheti, AK Trull, F Akhlaghi Therapeutic drug monitoring 27 (2), 116-122, 2005 | 38 | 2005 |
| Development of a population pharmacokinetic model for atorvastatin acid and its lactone metabolite R Narwal, F Akhlaghi, A Åsberg, M Hermann, SE Rosenbaum Clinical pharmacokinetics 49, 693-702, 2010 | 27 | 2010 |
| Review of methods in population pharmacokinetics AA Carter, SE Rosenbaum, MN Dudley Clinical research and regulatory affairs 12 (1), 1-21, 1995 | 21 | 1995 |
| Effect of variability in hepatic clearance on the bioequivalence parameters of a drug and its metabolite: simulations using a pharmacostatistical model SE Rosenbaum Pharmaceutica Acta Helvetiae 73 (3), 135-144, 1998 | 20 | 1998 |
| Problems encountered by the elderly in the use of conventional dosage forms MK Kottke, G Stetsko, SE Rosenbaum, CT Rhodes J Geriatr Drug Ther 5 (2), 77-89, 1990 | 19 | 1990 |
| Bioequivalence parameters of parent drug and its first-pass metabolite: comparative sensitivity to sources of pharmacokinetic variability SE Rosenbaum, J Lam Drug development and industrial pharmacy 23 (3), 337-344, 1997 | 18 | 1997 |
| Population pharmacokinetics: fundamentals, methods and applications SE Rosenbaum, AA Carter, MN Dudley Drug development and industrial pharmacy 21 (9), 1115-1141, 1995 | 18 | 1995 |
| The application of population pharmacokinetics to the drug development process KA Jackson, SE Rosenbaum Drug development and industrial pharmacy 24 (12), 1155-1162, 1998 | 17 | 1998 |
| Dse and Limitations of the Truncated Area Under the Curve in Bioequivalence Testing AJ Romero, C Bon, E Johnson, SE Rosenbaum, CT Rhodes Clinical Research Practices and Drug Regulatory Affairs 8 (2), 123-151, 1990 | 16 | 1990 |
| Area Under the Cureve Estimation in Bioequivalence Studies SE Rosenbaum, CT Rhodes, C Bon Drug Development and Industrial Pharmacy 16 (1), 157-163, 1990 | 13 | 1990 |
| Adverse drug reaction reporting systems: the United Kingdom and the United States HD Scott, A Thacher, SE Rosenbaum, WJ Waters Jr, M Green Rhode Island medical journal 71 (5), 179-184, 1988 | 11 | 1988 |
| Interventions to increase physician participation in a voluntary reporting system: the Rhode Island Adverse Drug Reaction Reporting Project SE Rosenbaum, A Thacher-Renshaw, M Green, WJ Waters Clinical research and regulatory affairs 9 (4), 261-275, 1992 | 8 | 1992 |
| Practolol and its metabolites: tissue localization and retention in the hamster. SE Rosenbaum, WE Lindup, TC Orton Journal of Pharmacology and Experimental Therapeutics 234 (2), 485-490, 1985 | 7 | 1985 |
